KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cost of Revenue: 2021-2024

Historic Cost of Revenue for Aurinia Pharmaceuticals (AUPH) over the last 4 years, with Dec 2024 value amounting to $28.2 million.

  • Aurinia Pharmaceuticals' Cost of Revenue rose 35.49% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.4 million, marking a year-over-year increase of 4.72%. This contributed to the annual value of $28.2 million for FY2024, which is 99.66% up from last year.
  • Aurinia Pharmaceuticals' Cost of Revenue amounted to $28.2 million in FY2024, which was up 99.66% from $14.1 million recorded in FY2023.
  • Aurinia Pharmaceuticals' Cost of Revenue's 5-year high stood at $28.2 million during FY2024, with a 5-year trough of $1.1 million in FY2021.
  • In the last 3 years, Aurinia Pharmaceuticals' Cost of Revenue had a median value of $14.1 million in 2023 and averaged $16.0 million.
  • Data for Aurinia Pharmaceuticals' Cost of Revenue shows a peak YoY spiked of 419.16% (in 2022) over the last 5 years.
  • Over the past 4 years, Aurinia Pharmaceuticals' Cost of Revenue (Yearly) stood at $1.1 million in 2021, then skyrocketed by 419.16% to $5.7 million in 2022, then spiked by 149.79% to $14.1 million in 2023, then spiked by 99.66% to $28.2 million in 2024.